Very low

Life Sciences & Pharmaceuticals

COVID-19 has resulted in an unprecedented focus on innovation and partnerships to develop drugs and vaccines across the sector.

Sector trends & challenges

  • Collaboration

    COVID-19 has resulted in an unprecedented focus on innovation and partnerships. Knowledge sharing and collaboration to develop vaccines between pharma companies may further strengthen the UK and Europe’s position in the sector.

  • Long-term investment

    There is likely to be an increase in future investment from national governments and the WHO on developing greater pandemic and disease resilience. However, there will remain a strong requirement to show value for money for R&D.

  • Regulatory changes

    Concerns remain over potential regulatory challenges following Brexit and there is an increased focus on the use of data - patient data, predominantly - across the sector.

Sector rating profile

The team at Interpath have observed a fairly limited volume of restructuring activity in the sector over the longer term. The sector's primary role in helping the global economy get back to work will likely elevate the sector yet further as a prized and protected asset. We continue to keep a close eye on the market and note emerging geo-political distrust over the vaccine rollout which is progressing at materially different rates elsewhere in the world.

Life Sciences & Pharmaceuticals

The British pharmaceutical sector is at the centre of global efforts to stop the spread of COVID-19. The aftermath of the crisis is likely to result in increased investment developing new vaccines and antibiotics to increase human resilience to future health emergencies.

The pandemic has resulted in an unprecedented focus on innovation and partnerships to develop drugs and vaccines, including how to bring to market safely. Additionally, there is growing use of technology to restructure pharmaceutical supply chains. Knowledge sharing and collaboration to develop vaccines between pharmaceutical companies may further strengthen the UK and Europe’s position globally.

There is likely to be an increase in future investment from national governments and intergovernmental bodies to develop greater pandemic and disease resilience. Building up research and manufacturing capacity have long lead times and there will remain a strong requirement to show value for money for R&D.

Concerns remain over potential regulatory changes following Brexit. There is an increased focus on the use of data, and patient data in particular, across the sector. In common with many other industries, the increasing pace of innovation is providing great opportunities for those willing to adapt.

Find Your Expert

Nigel Carr is Interpath Sector Lead for Life Sciences & Pharmaceuticals. For a full list of our senior people with experience in this sector use the button below.

Our senior team